Pharmacogenetic Associations of {beta}1-Adrenergic Receptor Polymorphisms With Cardiovascular Outcomes in the SPS3 Trial (Secondary Prevention of Small Subcortical Strokes) [Clinical Sciences]

Conclusion—Among individuals with previous small artery ischemic stroke, the ADRB1 Gly49 polymorphism was associated with MACE, particularly small artery ischemic stroke, a risk that may be increased among β-blocker-treated individuals. Further research is needed to define β-blocker benefit among ischemic stroke patients by ADRB1 genotype.Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00059306.

Source: Stroke - April 24, 2017 Category: Neurology Authors: Oyunbileg Magvanjav, Caitrin W. McDonough, Yan Gong, Leslie A. McClure, Robert L. Talbert, Richard B. Horenstein, Alan R. Shuldiner, Oscar R. Benavente, Braxton D. Mitchell, Julie A. Johnson Tags: Clinical Studies, Cardiovascular Disease, Genetic, Association Studies, Pharmacology, Ischemic Stroke Original Contributions Source Type: research